Across TCGA pan-cancer cohorts, ATG12P2 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of ATG12P2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where ATG12P2 RNA is repressed in tumor relative to normal tissue. In most cancer types ATG12P2 is over-expressed in tumor, although a few such as KIRC show the opposite, repressed pattern.

KIRC, STAD, and BRCA are the cancer types where ATG12P2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ATG12P2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	IV	−0.097	.004	6	view →
STAD	Male	II,III,IV	+0.287	.004	4	view →
BRCA	Female	All	+0.237	.009	4	view →
PRAD	All	All	+0.296	.016	2	view →
KICH	All	IV	+0.130	.033	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ATG12P2 RNA expression & survival · all ATG12P2 data types